Trial reportEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2026
Redefining response to cardiac resynchronization therapy: a post hoc analysis of the MORE-CRT MPP trial.
Trial report in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
aimsCardiac resynchronization therapy (CRT) response is commonly assessed at 6 months using left ventricular end-systolic volume (LVESV) and clinical endpoints. However, response may continue to evolve beyond this time point, with some initial non-responders subsequently improving or stabilizing. This study aimed to characterize changes in echocardiographic response from 6 to 12 months, identify predictors of these trajectories, and assess their relationship with longer-term clinical outcomes. METHODS AND
resultsThis post hoc analysis of the MORE-CRT MPP trial included patients receiving conventional biventricular pacing only. Patients were classified as non-responders (<15% LVESV reduction at 6 and 12 months), early responders (>15% reduction at 6 months), or delayed responders (<15% reduction at 6 months but >15% at 12 months). Six-month non-responders were further classified as stabilized (LVESV reduction at 12 months) or deteriorated (LVESV increase at 12 months). Heart failure hospitalization or death was analysed using restricted mean survival time and adjusted accelerated failure time models. Among 2732 patients (69.4% male; 62.8% non-ischaemic), event-free survival differed between early, delayed, and non-responders (P < 0.001). Non-responders had 52% shorter event-free survival than early responders (P < 0.001), and 38% shorter than delayed responders (P = 0.025). Early and delayed responders had similar outcomes (P = 0.221). Among non-responders, 39.0% stabilized and 61.0% deteriorated; outcomes diverged after 6 months (P < 0.001). The deterioration group had 59% shorter event-free survival (P < 0.001). Ischaemic aetiology, non-LBBB, and lower baseline LVEF predicted delayed response.
conclusionDelayed responders demonstrated similarly favourable clinical outcomes to early responders over the duration of follow-up. These findings support 12-month assessment and trajectory-based definitions of CRT response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.